Illinois House Bill HB3006

Illinois 2025-2026 Regular Session

• Introduced: 2/6/25
• Refer: 2/6/25
• Refer: 3/4/25
• Refer: 3/21/25

Caption

INS-HORMONE THERAPY-MENOPAUSE

Summary

HB3006 amends the Illinois Public Aid Code to expand Medicaid-style medical assistance coverage for hormone therapy used to treat menopause. Under current law referenced in the bill, coverage is limited to hormone therapy for menopause induced by a hysterectomy; this bill would remove that limitation and require coverage for medically necessary hormone therapy for menopause generally. The measure is framed as a health coverage update rather than a broader restructuring of the medical assistance program. The bill is effective immediately if enacted, meaning the coverage change would take effect without delay. It would directly affect the Illinois medical assistance program and the beneficiaries who rely on it, particularly patients seeking hormone therapy for menopausal symptoms who do not have a hysterectomy-related diagnosis. It also affects the scope of covered services and the state’s obligations to reimburse medically necessary treatment under the Public Aid Code.

Impact

HB3006 would amend Section 5-56 of the Illinois Public Aid Code to broaden the medical assistance program’s required coverage for hormone therapy. The practical legal effect is to replace a narrow eligibility standard—menopause induced by hysterectomy—with a broader standard covering medically necessary hormone therapy for menopause generally. This would likely expand access to treatment for Medicaid recipients and could increase state program expenditures depending on utilization and provider billing.

Sentiment

No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, support, or opposition in the available materials. Based on the bill text and caption, the measure appears to be a targeted health coverage expansion focused on menopause treatment. The absence of recorded controversy suggests the bill was introduced as a straightforward benefits clarification, though the fiscal implications of expanded coverage could still draw interest in later proceedings.

Contention

The main potential point of contention is the scope and cost of expanding coverage beyond hysterectomy-induced menopause to all medically necessary menopause-related hormone therapy. Supporters would likely emphasize improved access to care and alignment of coverage with medical necessity, while critics may focus on state spending, program eligibility standards, or the need for clinical safeguards around hormone therapy. Because no transcripts or votes are available, specific positions by legislators, agencies, or advocacy groups cannot be identified from the record provided.